Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy
Authors:
- 1 March 2017
- journal article
- review article
- Published by Elsevier in European Journal of Cancer
- Vol. 74, 1-8
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancerEuropean Journal of Cancer, 2013
- Impact of breast cancer on anti-mullerian hormone levels in young womenBreast Cancer Research and Treatment, 2012
- Tests for ovarian reserve: reliability and utilityCurrent Opinion in Obstetrics and Gynecology, 2010
- Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancerFertility and Sterility, 2010
- Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patientsBMC Cancer, 2010
- Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane eraAnti-Cancer Drugs, 2009
- Breast cancer in young women and its impact on reproductive functionHuman Reproduction Update, 2009
- Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancerBreast Cancer Research and Treatment, 2008
- A Pilot Study of Predictive Markers of Chemotherapy-Related Amenorrhea Among Premenopausal Women with Early Stage Breast CancerCancer Investigation, 2008
- Predictors of ovarian reserve in young women with breast cancerBritish Journal of Cancer, 2007